View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

IBA – TRANSPARENCY NOTIFICATION

IBA – TRANSPARENCY NOTIFICATION (Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, February 25, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world’s leading provider of proton therapy solutions for the treatment of cancer, announces that it has to issue a transparency notification, in accordance with Article 14, al. 1 of the Transparency Law of May 2, 2007 on disclosure of major holdings, further to the notification received on February 13, 2026. In its notification, Premier Miton Group plc indi...

 PRESS RELEASE

IBA SA – NOTIFICATION TRANSPARENCE

IBA SA – NOTIFICATION TRANSPARENCE (article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 25 février 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, annonce devoir effectuer une notification en matière de transparence conformément à l'article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes (« loi transparence »), à la suite d’une notification reçue le ...

 PRESS RELEASE

ASML publishes 2025 Annual Reports

ASML publishes 2025 Annual Reports ASML publishes 2025 Annual Reports VELDHOVEN, the Netherlands, February 25, 2026 – Today, ASML Holding NV (ASML) has published its 2025 Annual Reports. The 2025 Annual Reports 'Powering technology forward with you', highlight ASML’s commitment to advancing innovation by developing technology that enables more powerful and energy-efficient microchips that have the potential to address some of humanity's toughest challenges. Our ongoing innovation relies on strong partnerships across the global semiconductor ecosystem – together we create sustainable solu...

Barco NV: 1 director

A director at Barco NV bought 849,270 shares at 10.980EUR and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

 PRESS RELEASE

IBA – ACQUISITION OF OWN SHARES

IBA – ACQUISITION OF OWN SHARES Louvain-la-Neuve, Belgium, February 23rd, 2026 – 6 PM CET – In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA”) hereby discloses information in relation to its share buyback program announced on February 2nd, 2026. Under this program, IBA has requested a financial intermediary to repurchase up to 400,000 IBA ordinary shares on its behalf under the terms of a mandate with validity until September 30th, 2026 (included), effective as from February 3rd, 20...

 PRESS RELEASE

IBA – ACQUISITION D’ACTIONS PROPRES

IBA – ACQUISITION D’ACTIONS PROPRES Louvain-la-Neuve, Belgique, 23 février 2026 – 18h00 – Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") communique par la présente certaines informations relatives à son programme de rachat d'actions annoncé le 2 février 2026. Dans le cadre de ce programme, IBA a demandé à un intermédiaire financier de racheter en son nom un maximum de 400.000 actions ordinaires IBA selon les termes d'un mandat valable jusqu'au 30 septembre 2026 et effectif à part...

 PRESS RELEASE

ASML reports transactions under its current share buyback program

ASML reports transactions under its current share buyback program ASML reports transactions under its current share buyback program VELDHOVEN, the Netherlands – ASML Holding N.V. (ASML) reports the following transactions, conducted under ASML's current share buyback program. DateTotal repurchased sharesWeighted average priceTotal repurchased value16-Feb-2619,343€1,192.43€23,065,11417-Feb-2621,263€1,181.53€25,122,80418-Feb-2620,458€1,220.41€24,967,12319-Feb-2620,314€1,232.30€25,032,93620-Feb-2620,134€1,241.69€25,000,237 ASML’s current share buyback program was announced on 28 January 2026, ...

Hilde Van Boxstael ... (+5)
  • Hilde Van Boxstael
  • Kristof Samoy
  • Michiel Declercq
  • Thibault Leneeuw
  • Wim Lewi
Kristof Samoy
  • Kristof Samoy

Arcadis Risk/Reward Not Yet Compelling in a Derating Sector

Arcadis surprised the market last week with weak FY results and disappointing 2026 guidance. We have overhauled our model and revisited our investment case. The repositioning of GBA Places announced after the IBI & DPS acquisitions in 2022 is not (yet) delivering the intended benefits, while the strategic shift toward large, higher margin projects is coinciding with slower and less predictable backlog conversion. With organic growth absent, the previously compelling deep discount valuation versu...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ahold Delhaize: Peer Walmart 4Q25/26 results. Arcadis: Main topics 4Q25/FY25 conference call. ASM: 4Q25 preview, FY26 should be strong. Brunel: 4Q25 result beats and trends stabilise; DACH back to growth in 1Q26; additional cost savings announced and special dividend. Cofinimmo: Beat on bottom line, strong investment outlook for 2026. IMCD: Another step in EMEA. Magnum Ice Cream Company: Peer Danone 4Q25 results. Recticel: Peer Kingspan FY25 results. Software sector: Cheaper code...

Kristof Samoy
  • Kristof Samoy

Arcadis Key take-aways analyst call

This morning Arcadis reported numbers (as written in a separate FRN) that were disappointing. Only the Resilience GBA and the cash collection process delivered in 4Q25. The sharp revenue revision for 2026 came as a cold surprise but the new CFO delivered on his cash collection commitment made late 2025. Together with the CEO nominee he outlaid a hands-on, pragmatic approach for a return to meaningful topline and margin growth. However this will be (again) back-end loaded in 2026 and mainly reali...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

AEGON: Uneventful results, US weaker, underlying OCG in line / Air France-KLM: Productivity gains starting to filter through / Arcadis: Weak revenues and EBITA, but strong NWC / Ascencio: Results in line, no concerns on Carrefour Belgium exposure / Azelis: Persisting softness in 4Q25, continued focus on costs and cash / BAM Group: Solid 2H25 results, 2026 outlook in line / Belgian telecoms: Telenet improved net adds, to relist as part of Ziggo in 2027, Liberty to sell half of its 66% Wyre stake ...

Kristof Samoy
  • Kristof Samoy

Arcadis First look: Only Resilience & cash collection delivered in 4Q2...

Arcadis released a disappointing set. Only Resilience posted an inline performance. Growth in Places in 4Q was -13% while our scenario was counting on a stabilisation (o% y/y). 4Q Traction in Mobility did not materialise as expected. Company guides for a transitional 2026 with flat growth well below our and css est. . Thanks to strong cash collection FCF was a clear positive surprise. Analyst call at 2pm CET. We will adjust our 2026 numbers downwards to the issued guidance. Hold.

Guy Sips ... (+9)
  • Guy Sips
  • Hilde Van Boxstael
  • Kristof Samoy
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Thibault Leneeuw
  • Thomas Couvreur
  • Wim Hoste
  • Wim Lewi

Morning Notes : ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HY...

: ABI BB, AGN NA, ARCAD NA, BESI NA, ENX FP, GIMB BB, HYL BB, IBAB BB, KIN BB, MTLS US, VGP BB, AZE BB, ZEAL DC

Martijn Den Drijver
  • Martijn Den Drijver
Mathijs Geerts Danau
  • Mathijs Geerts Danau

Hyloris Valacyclovir oral suspension is delayed

Hyloris provided an update regarding the review of valacyclovir for oral suspension which had a PDUFA target action date of 12 October 2025. It appears that the FDA identified significant inspection observations at the third party manufacturing plant in Greece. The manufacturer confirmed that it is actively implementing its remediation plans. Currently, Hyloris believes that resolution of the manufacturing situation is required to obtain an FDA product approval and is working on a solution. We r...

 PRESS RELEASE

IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre...

IBA et Shreeji signent un accord pour quatre cyclotrons afin d’étendre la production de radiopharmaceutiques TEP en Inde Louvain-la-Neuve, Belgium – 19 février 2026 – IBA (Ion Beam Applications S.A., EURONEXT), le leader mondial des technologies d'accélérateurs de particules et acteur de premier plan en médecine nucléaire, et Shreeji (Shreeji Imaging and Diagnostic Centre Pvt. Ltd.), l'un des principaux fabricants et distributeurs indiens de fluorodéoxyglucose (FDG) et de radiopharmaceutiques pour la tomographie par émission de positons (TEP), ont signé un contrat pour la livraison et l'i...

 PRESS RELEASE

Arcadis Q4 and Full Year 2025 Results: Mixed results, repositioning fo...

Arcadis Q4 and Full Year 2025 Results: Mixed results, repositioning for next growth phase PRESS RELEASE | Arcadis Fourth Quarter and Full Year Results 2025 Mixed results, repositioning for next growth phase FOURTH QUARTER Net revenues of €887 million, organic growth of -2.9%Operating EBITA margin of 10.8% (Q4‘24: 12.6%)Extensive Property & Investment (within Places) project portfolio review led to revenue adjustments Record free cash flow performance of €344 million (Q4‘24: €183 million) FULL YEAR Net revenues of €3.8 billion, organic growth -0.5% with areas of strength offset by Place...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch